15 December 2020
From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !
16 October 2020
1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Download abstract.
1 October 2020
Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.
1 July 2020
Orega Biotech announces the nomination of Jeremy Bastid as Chief Executive Officer (Directeur Général) effective as of July 1st, 2020. “I have worked with Jeremy since the inception of OREGA Biotech” commented Gilles Alberici, President of Octalfa and Chairman of OREGA Biotech. “He has played a prominent role in the development of the company, both on the R&D and the business aspects. No doubt that his promotion as CEO of OREGA Biotech will help the company to further grow”, he added. “I am honored to be appointed new CEO and look forward to leading OREGA Biotech with the support from our Board”, commented Jeremy Bastid. “I am thrilled to lead this remarkable team and I am grateful for our Board’s confidence”.
